Ordastobart
Based on 1 Customer Validation
Ordastobart (INBRX-106; ES-102) is a hexavalent OX40 agonist antibody. Ordastobart enhances OX40 receptor clustering, signaling, and downstream activation, thereby increasing the proliferation and activation of CD4+ and CD8+ T cells in vitro and in vivo. Ordastobart exhibits anti-tumor effects and improves survival in mouse models of cancer. Ordastobart is indicated for research in cancers such as fibrosarcoma and colorectal cancer.
For research use only. We do not sell to patients.
- Purity: 98%
- CAS No.: 2708115-83-5
- Molecular Weight:128.96 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Orexin Receptor (OX Receptor) Isoforms
More
Biological Activity
[G1 VH-VH-VH-h-CH2-CH3]-dimer
Human
TNFRSF4/OX40/CD134
Ordastobart (5-25 nM, 1 h at 37°C) induces high clustering of the OX40 receptor in CHO cells expressing a human OX40 extracellular domain coupled to GFP[1].
Ordastobart (0.001-1000 nM, 96 h) stimulates CD4+ and CD8+ cells enriched from PBMC[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CHO cells expressing a human OX40 extracellular domain coupled to GFP
-
Concentration:5, 25 nM
-
Incubation Time:1 h at 37°C
-
Result:Enhanced high-level co-occurrence of GFP (green) and AF647 (magenta) on the cell membrane.
-
Cell Line:CD4+ and CD8+ T cells enriched from healthy donor peripheral blood mononuclear cells (PBMC)
-
Concentration:0.001, 0.01, 0.1, 1, 10, 100, 1000 nM
-
Incubation Time:96 h at 37°C
-
Result:Increaseed human leukocyte antigen (HLA)-DR expression, with maximum activity reaching a peak between 0.1-10 nM and declining at concentrations above 10 nM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MCA-205 (C57BL/6) or CT26 (BALB/c) tumor-bearing (106) mice (6-8 weeks old, female) model[1]
-
Dosage:10 µg/single dose
-
Administration:i.v.
-
Result:Demonstrated good tolerability, reduced tumor size, and significantly improved survival.
Engaged and activated CD8+ T cells to control tumor growth.
Expanded CD8+ T cells within tumors and increases T cell frequency and proliferation within LNs; reduces CD8+ T cell frequency in tdLNs but increases proliferation Ki-67.
Increased CD4+ Teff proliferation as compared with controls, enhanced interferon (IFN)-γ and TNF-α production.
Increased the frequency of CD8+ T cells and decreased the frequency of Tregs compared with controls.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
VH-VH-VH-h-CH2-CH3
ELISA, FACS, Functional assay
-
Loaded Ordastobart on ProA biosensor, can bind OX40/TNFRSF4 Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78189) with an affinity constant of 1.30E-10 M as determined in BLI assay.
Chemical Information
-
CAS No. 2708115-83-5
-
Appearance Liquid
-
Molecular Weight 128.96 kDa
-
Color Colorless to light yellow
-
SMILES
[Ordastobart]
-
Synonyms
INBRX-106; ES-102
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)